Open saccharin-based secondary sulfonamides as potent and selective inhibitors of cancer-related carbonic anhydrase IX and XII isoforms

D'Ascenzio, Melissa; Guglielmi, Paolo; Carradori, Simone; Secci, Daniela; Florio, Rosalba; Mollica, Adriano; Ceruso, Mariangela; Akdemir, Atilla; Sobolev, Anatoly P.; Supuran, Claudiu T.

Published in:
Journal of Enzyme Inhibition and Medicinal Chemistry

DOI:
10.1080/14756366.2016.1235040

Publication date:
2017

Document Version
Final published version

Link to publication in Discovery Research Portal

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying the publication in the public portal.
Open saccharin-based secondary sulfonamides as potent and selective inhibitors of cancer-related carbonic anhydrase IX and XII isoforms

Melissa D'Ascenzio, Paolo Guglielmi, Simone Carradori, Daniela Secci, Rosalba Florio, Adriano Mollica, Mariangela Ceruso, Atilla Akdemir, Anatoly P. Sobolev & Claudiu T. Supuran

To cite this article: Melissa D’Ascenzio, Paolo Guglielmi, Simone Carradori, Daniela Secci, Rosalba Florio, Adriano Mollica, Mariangela Ceruso, Atilla Akdemir, Anatoly P. Sobolev & Claudiu T. Supuran (2017) Open saccharin-based secondary sulfonamides as potent and selective inhibitors of cancer-related carbonic anhydrase IX and XII isoforms, Journal of Enzyme Inhibition and Medicinal Chemistry, 32:1, 51-59, DOI: 10.1080/14756366.2016.1235040

To link to this article: http://dx.doi.org/10.1080/14756366.2016.1235040
Open saccharin-based secondary sulfonamides as potent and selective inhibitors of cancer-related carbonic anhydrase IX and XII isoforms

Melissa D’Ascenziola, Paolo Guglielmi1b, Simone Carradoric, Daniela Secci1b, Rosalba Florio1c, Adriano Mollica1c, Mariangela Cersusod, Atilla Akdemire, Anatoly P. Sobolevf and Claudiu T. Supuran1g

School of Life Sciences, University of Dundee, Dundee, Scotland, UK; Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza University of Rome, Rome, Italy; Department of Pharmacy, “G. D’Annunzio” University of Chieti-Pescara, Chieti, Italy; Laboratorio di Chimica Bioorganica, Università degli Studi di Firenze, Sesto Fiorentino, Florence, Italy; Department of Pharmacology, Faculty of Pharmacy, Bezmialem Vakif University, Fatih, Istanbul, Turkey; Magnetic Resonance Laboratory “Annalaura Segre”, National Research Council, Institute of Chemical Methodologies, Monterotondo, Rome, Italy; Neurofarba Department, Section of Pharmaceutical and Nutriceutical Sciences, Università degli Studi di Firenze, Sesto Fiorentino, Florence, Italy

ABSTRACT
A large number of novel secondary sulfonamides based on the open saccharin scaffold were synthesized and evaluated as selective inhibitors of four different isoforms of human carbonic anhydrase (hCA I, II, IX and XII, EC 4.2.1.1). They were obtained by reductive ring opening of the newly synthesized N-alkylated saccharin derivatives and were shown to be inactive against the two cytosolic off-target hCA I and II (Ks > 10 μM). Interestingly, these compounds inhibited hCA IX in the low nanomolar range with Ks ranging between 20 and 298 nM and were extremely potent inhibitors of hCA XII isozyme (Ks ranging between 4.3 and 432 nM). Since hCA IX and XII are the cancer-related isoforms recently validated as drug targets, these results represent an important goal in the development of new anticancer candidates. Finally, a computational approach has been performed to better correlate the biological data to the binding mode of these inhibitors.

Introduction
Carbonic anhydrases are a vast family of metalloenzymes (CAs, EC 4.2.1.1) strongly involved in regulating cell homeostasis and intracellular pH by catalyzing the reversible hydration of carbon dioxide to bicarbonate ions1. Fifteen human isoforms are discovered to date and can be differentiated on the basis of cellular localization, tissue distribution, catalytic activity and affinity to various inhibitors, thus representing validated therapeutic targets for the treatment of a wide range of diseases2,3. In particular, hCA IX and XII were identified as part of the complex machinery that primary and metastatic cancer cell lines use to compensate their dysregulated pH in poorly vascularized microenvironments, like the surroundings of solid tumours4–6. Targeting these cancer-related isoforms has attracted a lot of attention, hence leading to the proliferation of literature on the subject and the development of structurally diverse inhibitors7–19. As a result of this superb effort, a potent hCA IX selective compound (SLC-0111) is currently in Phase I clinical trials for the treatment of solid metastatic tumors, consequently boosting the research for new suitable candidates20,21.

Since the active site of CAs is characterized by the presence of a catalytic zinc ion hold in place by three histidine residues, one of the most successful approaches to design novel CAIs implies introducing a zinc-binding group (ZBG) in the scaffold of potential inhibitors22. In fact, the most widely prescribed CAIs are characterized by the presence of a primary sulfonamide group, which efficiently engages the positively charged zinc ion upon deprotonation23–26. However, despite primary sulfonamides being preferred “zinc binding group”, they are usually associated with promiscuous profiles and lack of selectivity amongst the different isoforms. On the other side, secondary and tertiary sulfonamides have been lately reported in the literature as efficient and selective inhibitors of the cancer-related hCA IX and XII isoforms27–31, although their binding mode remains a subject of investigation32. In a recent publication, Ivanova et al. reported on the spontaneous ring opening of cyclic tertiary sulfonamides under basic (pH ~9) crystallization conditions33. Since hCAs do not possess any peptidase activity, they concluded that the base-catalyzed hydrolysis of the saccharin isothiazolone ring happened before the inhibitor entered the active site, and proved their hypothesis by testing both open and closed analogs against a panel of hCAs (hCA I, hCA II, hCA IX and hCA XII). In particular, these open saccharin derivatives determined an increased inhibition of hCA IX, while retaining high activity against hCA II. Such promising results prompted us to investigate the effects of ring opening on our previously reported N-substituted saccharins as selective inhibitors of CA IX and XII19,34. In this paper, we used a reductive ring opening approach to induce the 5-membered isothiazolone ring of saccharin to collapse into its corresponding secondary sulfonamide and benzyl alcohol (Figure 1)35. The rationale behind this choice could be found in the opportunity of generating two new potential anchoring points for the zinc ion, while introducing several
degrees of freedom to the bonds connecting the two hydrophobic phenyl substituents to the polar core of the molecule. In general, the newly synthesized compounds (1–21) proved to be as potent as or slightly less potent than parent inhibitors, while the selectivity for the cancer-related isoforms (hCA IX and XII) over the off-target hCA I and II improved dramatically. In fact, none of the reported compounds inhibited hCA I and II isoforms at concentrations lower than 10 μM, while Ki values spanned from 20 to 298 nM against hCA IX and from 4.3 to 382 nM against hCA XII.

Chemistry

Saccharin (1.0 eq.) was activated using freshly ground anhydrous potassium carbonate and the corresponding salt was then directly reacted with a proper electrophile (2 eq. of substituted benzyl halide or α-haloacetophenone) by stirring the reaction mixture in N,N-dimethylformamide at 80 °C overnight (Scheme 1). Following these optimized conditions (polar aprotic solvent), we strictly obtained only the more stable regioisomers (N-substituted saccharin derivatives) limiting the Chapman–Mumm thermal rearrangement to the less stable O-substituted counterparts.

N-substituted saccharin derivatives were then subjected to reductive ring opening with an excess of NaBH4 in dry methanol at room temperature for 2–8 h to give the corresponding secondary sulfonamide compounds 1–21 in discrete yields following a previously reported procedure with slight modifications.

Our choice of NaBH4 as a reducing agent depended on preliminary experiments which suggested that (i) the sulfone group was not affected by these mild reducing conditions leading to the carbonyl group reduction to the alcohol level only with saccharin ring cleavage and that (ii) similar results were obtained for the preparation of o-hydroxymethyl-N-alkyl-benzamides starting from N-alkyl-phthalimides.

In their IR spectra, we usually registered for the open saccharin derivatives new but expected signals for the OH and NH stretching at 3240 and 3470 cm⁻¹, respectively, and the disappearance of the C=O stretching at 1735 cm⁻¹.

Biological evaluation

All the synthesized compounds were tested to evaluate their inhibitory activity towards the ubiquitous off-target isoforms, hCA I and II, and the cancer-related ones, hCA IX and XII, by a stopped-flow, CO₂ hydrase assay method and their CA inhibition data (Ki) are summarized in Table 1.

Experimental protocols

General

Solvents and reagents were used as supplied without further purification. Where mixtures of solvents are specified, the stated ratios are volume:volume. Acetazolamide was purchased by Sigma-Aldrich (Italy) and used in the biological assays without further purification. All synthesized compounds have been fully characterized by analytical and spectral data. Column chromatography was carried out using Sigma-Aldrich silica gel (high-purity grade, pore size 60 Å, 200–425 mesh particle size). Analytical thin-layer chromatography was carried out on Sigma-Aldrich silica gel on TLA aluminum foils with fluorescent indicator. Visualization was carried out under UV irradiation (254 nm). ¹H-NMR spectra were recorded on a Bruker AV400 (¹H: 400 MHz, ¹3C: 101 MHz). ¹⁹F-NMR spectra were recorded on a Bruker AVANCE 600 spectrometer (¹⁹F: 564.7 MHz). Chemical shifts are quoted in ppm, based on appearance rather than interpretation, and are referenced to the residual non deuterated solvent peak. In the case of ¹⁹F, chemical shifts...
are referenced to an external standard (CF₃COOH, δ = 76.55 ppm). Infrared spectra were recorded on a Bruker Tensor 27 FTIR spectrometer equipped with an attenuated total reflectance attachment with internal calibration. Absorption maxima (νmax) are reported in wavenumbers (cm⁻¹). All melting points were measured on a Stuart® melting point apparatus SMP1 and are uncorrected. Temperatures are reported in °C. Where given, systematic compound names are those generated by ChemBioDraw Ultra® 12.0 following IUPAC conventions. NMR spectra for some representative compounds could be found in the Supplemental material.

**Procedures for the synthesis of the new open saccharin derivatives**

2-(Hydroxymethyl)-N-(2-methylbenzyl)benzenesulfonamide (1)

(2-Methylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH₄ was added portionwise and the reaction monitored by TLC. After 2 h the reaction was quenched with water and the aqueous phase was extracted with dichloromethane (3 × 30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo to give the title compound as a light brown solid (37% yield); mp 103–105°C; IR νmax 3380 (ν O–H), 3258 (ν N–H), 2973 (ν C=O–H), 1522 (ν N–O), 1327 (ν/ς S=O), 1165 (ν/ς S=O), 698 (δ Csp2-H) cm⁻¹; ¹H-NMR (400 MHz, DMSO-d₆) δ 4.34 (d, 2H, J = 5.6 Hz, CH₂), 4.88 (s, 2H, CH₂), 5.45 (bs, 1H, OH, D₂O exch.), 7.39 (t, 1H, J = 7.2 Hz, CH₃α), 7.50 (t, 1H, J = 7.6 Hz, CH₃β), 7.60–7.68 (m, 6H, 3 x CH₃β), 7.74–7.79 (m, 2H, 2 x CH₃α), 7.96 (d, 1H, J = 8.4 Hz, CH₃β), 8.29 (bs, 1H, NH, D₂O exch.). ¹³C-NMR (101 MHz, DMSO-d₆) δ 43.4 (CH₃β), 60.0 (CH₂), 125.1 (Ar), 127.3 (Ar), 128.2 (Ar), 128.5 (Ar), 128.9 (Ar), 129.6 (Ar), 129.9 (Ar), 130.5 (Ar), 131.6 (Ar), 133.2 (Ar), 134.1 (Ar), 136.6 (Ar), 138.2 (Ar).

2-(Hydroxymethyl)-N-(2-trifluoromethylbenzyl)benzenesulfonamide (2)

(2-Trifluoromethylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH₄ was added portionwise and the reaction monitored by TLC. After 4 h the reaction was quenched with water and the aqueous phase was extracted with dichloromethane (3 × 30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column chromatography (EtOAc/n-hexane, 1:4). The title compound was a white solid (52% yield); mp 64–66°C; IR νmax 3459 (ν O=H), 3237 (ν N=H), 3065 (ν Csp2-H), 1319 (ν/ς S=O), 1167 (ν/ς S=O), 712 (δ Csp2-H) cm⁻¹; ¹H-NMR (400 MHz, CDCl₃) δ 2.25 (s, 3H, CH₃α), 2.77 (bs, 1H, OH, D₂O exch.), 4.08 (s, 2H, CH₂), 5.01 (s, 2H, CH₂), 5.43 (bs, 1H, NH, D₂O exch.), 7.09–7.19 (m, 4H, CH Ar), 7.47–7.61 (m, 3H, CH₃β), 8.01–8.04 (m, 1H, CH₃α); ¹³C-NMR (101 MHz, CDCl₃) δ 18.7 (CH₃β), 45.5 (CH₃α), 64.2 (CH₂), 126.2 (Ar), 128.2 (Ar), 128.5 (Ar), 128.9 (Ar), 129.6 (Ar), 129.9 (Ar), 130.5 (Ar), 131.6 (Ar), 133.2 (Ar), 134.1 (Ar), 136.6 (Ar), 138.2 (Ar).

2-(Hydroxymethyl)-N-(2-nitrobenzyl)benzenesulfonamide (3)

(2-Nitrobenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH₄ was added portionwise and the reaction monitored by TLC. After 6 h the reaction was quenched with water and the aqueous phase was extracted with dichloromethane (3 × 30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column chromatography (EtOAc/n-hexane, 2:1). The title compound was a white solid (0.05 g, 11% yield); mp 162–164°C; IR νmax 3273 (ν O=H and ν N=H), 2920 (ν C=O–H), 1402 (ν/ς S=O), 1065 (ν/ς S=O), 676 (δ Csp2-H) cm⁻¹; ¹H-NMR (400 MHz, CDCl₃) δ 3.45 (bs, 1H, OH, D₂O exch.), 4.14 (d, 2H, J = 6.4 Hz, CH₂), 4.93 (s, 2H, CH₂), 6.18 (m, 1H, NH, D₂O exch.), 7.03 (t, 1H, J = 7.6 Hz, CH₃β), 7.15 (t, 1H, J = 7.4 Hz, CH₃α), 7.28 (d, 1H, J = 6.8 Hz, CH₃β), 7.33–7.49 (m, 4H, CH Ar), 7.87 (d, 1H, J = 8.0 Hz, CH₃α); ¹³C-NMR (101 MHz, CDCl₃) δ 47.4 (CH₂), 63.5 (CH₃β), 123.4 (Ar), 123.6 (Ar), 128.3 (Ar), 129.4 (Ar), 129.6 (Ar), 130.3 (Ar), 131.3 (Ar), 132.7 (Ar), 133.1 (Ar), 135.6 (Ar), 137.8 (Ar), 138.4 (Ar).

2-(Hydroxymethyl)-N-(3-methylbenzyl)benzenesulfonamide (4)

(3-Methylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH₄ was added portionwise and the reaction monitored by TLC. After 7 h the reaction was quenched with water and the aqueous phase was extracted with dichloromethane (3 × 30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column chromatography (EtOAc/n-hexane, 1:4). The title compound was a white solid (51% yield); mp 79–80°C; IR νmax 3431 (ν O=H), 3161 (ν N=H), 2936 (ν C=O–H), 1316 (ν/ς S=O), 1152 (ν/ς S=O), 694 (δ Csp2-H) cm⁻¹; ¹H-NMR (400 MHz, CDCl₃) δ 2.27 (s, 3H, CH₃α), 2.80 (bs, 1H, OH, D₂O exch.), 4.07 (bs, 2H, CH₂), 4.99 (s, 2H, CH₂), 5.72 (bs, 1H, NH, D₂O exch.), 6.96 (d, 2H, J = 7.6 Hz, CH₃β), 7.04 (d, 1H, J = 8.0 Hz, CH₃α), 7.14 (t, 1H, J = 7.4 Hz, CH₃β), 7.44–7.49 (m, 2H, CH Ar), 7.55–7.59 (m, 1H, CH₃β), 7.98 (d, 1H, J = 7.8 Hz, CH₃α); ¹³C-NMR (101 MHz, CDCl₃) δ 21.3 (CH₃β), 47.5 (CH₂), 63.8 (CH₂), 124.9 (Ar), 128.4 (Ar), 128.5 (Ar), 128.6 (Ar), 128.7 (Ar), 129.8 (Ar), 131.5 (Ar), 133.1 (Ar), 136.1 (Ar), 138.1 (Ar), 138.2 (Ar), 138.3 (Ar).

2-(Hydroxymethyl)-N-(3-trifluoromethylbenzyl)benzenesulfonamide (6)

(3-Trifluoromethylbenzyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH₄ was added portionwise and the reaction monitored by TLC. After 8 h the reaction was quenched with water and the aqueous phase was extracted with dichloromethane (3 × 30 mL). The organic layers were reunited, dried over
sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column chromatography (EtOAc/n-hexane, 1:3). The title compound was a white solid (71% yield); mp 76–78 °C; IR \( \nu_{\text{max}} \) 3430 (ν O–H), 3278 (ν N–H), 1317 (ν as S=O), 1160 (ν s, S=O), 700 (δ Csp²–H) cm⁻¹; ¹H-NMR (400 MHz, CDCl₃) δ 2.98 (t, 1H, J = 4.8 Hz, OH, D₂O exch.), 4.06 (d, 2H, J = 6.4 Hz, CH₂), 4.91 (d, 2H, J = 4.0 Hz, CH₂), 6.07 (m, 1H, NH, D₂O exch.), 7.24–7.37 (m, 6H, CH₃), 7.42–7.46 (m, 1H, CH₃), 7.82 (d, 1H, J = 7.6 Hz, CH₃); ¹³C-NMR (101 MHz, CDCl₃) δ 46.9 (CH₃), 63.9 (CH₃), 123.9 (C-F), 127.3 (C-F) cm⁻¹; ¹⁹F-NMR (564.7 MHz, CDCl₃) δ -60.09 (s, CF₃).

N-(3-fluorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (8)

(3-Fluorobenzyl)benzal[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH₄ was added portionwise and the reaction monitored by TLC. After 6 h the reaction was quenched with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column chromatography (EtOAc/n-hexane, 1:4). The title compound was a white solid (56% yield); mp 100–102 °C; IR \( \nu_{\text{max}} \) 3437 (ν O–H), 3130 (ν N–H), 2930 (ν Csp³–H), 1310 (ν as S=O), 1151 (ν s, S=O), 701 (δ Csp²–H) cm⁻¹; ¹H-NMR (400 MHz, CDCl₃) δ 2.31 (s, 3H, CH₃), 2.80 (s, 1H, OH, D₂O exch.), 4.07 (d, 2H, J = 5.2 Hz, CH₂), 4.99 (s, 2H, CH₂), 5.60 (bs, 1H, NH, D₂O exch.), 7.06 (bs, 4H, CH₃), 7.44–7.50 (m, 2H, CH₂), 7.55–7.60 (m, 1H, CH₃), 8.00 (d, 1H, J = 7.6 Hz, CH₂); ¹³C-NMR (101 MHz, CDCl₃) δ 21.1 (CH₃), 47.3 (CH₃), 63.8 (CH₃), 127.9 (Ar), 128.5 (Ar), 129.3 (Ar), 129.9 (Ar), 131.6 (Ar), 133.1 (Ar), 133.2 (Ar), 137.6 (Ar), 138.1 (Ar), 138.2 (Ar).

N-(3-bromobenzyl)-2-(hydroxymethyl)benzenesulfonamide (9)

N-(3-bromobenzyl)benzal[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH₄ was added portionwise and the reaction monitored by TLC. After 5 h the reaction was quenched with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column chromatography (EtOAc/n-hexane, 1:3). The title compound was a white solid (79% yield); mp 78–80 °C; IR \( \nu_{\text{max}} \) 3417 (ν O–H), 3161 (ν N–H), 3065 (ν Csp²–H), 1321 (ν as S=O), 1157 (ν s, S=O), 688 (δ Csp²–H) cm⁻¹; ¹H-NMR (400 MHz, CDCl₃) δ 3.03 (bs, 1H, OH, D₂O exch.), 4.15 (d, 2H, J = 6.4 Hz, CH₂), 5.02 (d, 2H, J = 5.2 Hz CH₂), 6.14 (t, 1H, J = 6.4 Hz, NH, D₂O exch.), 7.32 (d, 2H, J = 8.0 Hz, CH₂), 7.40–7.49 (m, 4H, CH₃), 7.54–7.58 (m, 1H, CH₃), 7.91 (s, 1H, CH₃); ¹³C-NMR (101 MHz, CDCl₃) δ 46.9 (CH₃), 63.9 (CH₃), 124.0 (C-F), 127.3 (C-F) cm⁻¹; ¹⁹F-NMR (564.7 MHz, CDCl₃) δ -60.08 (s, CF₃).

N-(4-cyanobenzyl)-2-(hydroxymethyl)benzenesulfonamide (12)

(4-Cyanobenzyl)benzal[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH₄ was added portionwise and the reaction monitored by TLC. After 8 h the reaction was quenched with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column chromatography (EtOAc/n-hexane, 1:1). The title compound was a white solid (70% yield); mp 75–76 °C; IR \( \nu_{\text{max}} \) 3454 (ν O–H), 3214 (ν N–H), 2955 (ν Csp³–H), 1319 (ν as S=O), 1156 (ν s, S=O), 694 (δ Csp²–H) cm⁻¹; ¹H-NMR (400 MHz, DMSO-d₆) δ 4.00 (d, 2H, J = 6.2 Hz, CH₂), 4.87 (d, 2H, J = 5.2 Hz, CH₂), 5.42 (bs, 1H, OH, D₂O exch.), 7.20 (bs, 2H, CH₂), 7.38 (bs, 3H, CH₃), 7.59–7.63 (m, 1H, CH₃), 7.75–7.78 (m, 2H, CH₂), 8.23 (bs, 1H, NH, D₂O exch.); ¹³C-NMR (101 MHz, DMSO-d₆) δ 45.6 (CH₃), 59.9 (CH₂), 122.0 (Ar), 127.0 (Ar), 127.2 (Ar), 127.9 (Ar), 128.5 (Ar), 130.4 (Ar), 130.7 (Ar), 130.8 (Ar), 132.9 (Ar), 137.2 (Ar), 141.2 (Ar), 141.5 (Ar).
sulfate and concentrated in vacuo to give a crude product, which was purified by column chromatography (EtOAc/n-hexane, 1:1). The title compound was a white solid (67% yield); mp 93–95 °C; IR max 3458 (ν O–H), 3236 (ν N–H), 2876 (ν Csp3–H), 1314 (ν Csp2–H); 1H-NMR (400 MHz, CDCl3) δ 2.90 (2H, 1H, OH, D2O exch.), 4.06 (d, 2H, J = 6.0 Hz, CH2), 5.01 (s, 2H, CH2). 5.88 (bs, 1H, NH, D2O exch.), 7.11 (d, 2H, J = 8.4 Hz, CH2), 7.21 (d, 2H, J = 8.4 Hz, CH2), 7.43–7.49 (2H, CH2), 7.50–7.60 (1H, CH2), 7.95 (d, 1H, J = 7.6 Hz, CH2); 13C-NMR (101 MHz, CDCl3) δ 46.8 (CH2), 63.9 (CH2), 128.6 (Ar), 128.7 (Ar), 129.3 (Ar), 129.8 (Ar), 131.6 (Ar), 133.2 (Ar), 133.7 (Ar), 134.8 (Ar), 137.9 (Ar), 138.1 (Ar).

N-(4-bromobenzyl)-2-(hydroxymethyl)benzenesulfonamide (16)
(4-Bromobenzyl)benz[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the reaction monitored by TLC. After 7 h the reaction was quenched with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column chromatography (EtOAc/n-hexane, 1:2). The title compound was a white solid (53% yield); mp 124–125 °C; IR max 3461 (ν O–H), 3234 (ν N–H), 3064 (ν Csp2–H), 1314 (ν Csp2–H); 1H-NMR (400 MHz, CDCl3) δ 2.71 (bs, 1H, NH, D2O exch.), 4.06 (bs, 2H, CH2), 5.03 (s, 2H, CH2), 5.78 (bs, 1H, NH, D2O exch.), 7.06–7.08 (2H, CH2), 7.37–7.59 (5H, CH2), 7.96–7.97 (1H, CH2); 13C-NMR (101 MHz, CDCl3) δ 46.9 (CH2), 64.1 (CH2), 121.9 (Ar), 128.6 (Ar), 129.6 (Ar), 129.8 (Ar), 131.7 (Ar), 133.2 (Ar), 137.9 (Ar), 138.3 (Ar).

N-(4-fluorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (14)
(4-Fluorobenzyl)benz[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the reaction monitored by TLC. After 7 h the reaction was quenched with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column chromatography (EtOAc/n-hexane, 1:1). The title compound was a white solid (76% yield); mp 123–130 °C; IR max 3495 (ν O–H), 3159 (ν N–H), 2958 (ν Csp3–H), 1330 (ν Csp2–H), 1140 (ν Csp2–H); 1H-NMR (400 MHz, CDCl3) δ 2.72 (bs, 1H, OH, D2O exch.), 4.23 (s, 2H, CH2), 4.89 (bs, 2H, CH2), 5.04 (bs, 1H, NH, D2O exch.), 6.79–6.83 (2H, CH2), 6.70–6.79 (2H, CH2), 7.10–7.14 (1H, CH2), 7.26 (s, 1H, CH2), 7.33–7.48 (2H, CH2), 7.92–7.94 (1H, CH2); 13C-NMR (101 MHz, CDCl3) δ 35.1 (CH3), 63.6 (CH2), 111.2 (Ar–F, 1JC–F = 24.8 Hz), 128.3 (Ar), 129.7 (Ar), 130.0 (Ar), 130.1 (Ar), 131.2 (Ar), 133.1 (Ar), 137.8 (Ar), 138.2 (Ar), 161.2 (Ar–F, 1JC–F = 24.69 Hz); 19F-NMR (564.7 MHz, CDCl3) δ -112.08 (t, JF–H = 6.9 Hz, CF).

N-(3,4-dichlorobenzyl)-2-(hydroxymethyl)benzenesulfonamide (18)
(3,4-Chlorobenzyl)benz[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH4 was added portionwise and the reaction monitored by TLC. After 7 h the reaction was quenched with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column chromatography (EtOAc/n-hexane, 2:1). The title compound was a light brown solid (81% yield); mp 83–84 °C; IR max 3463 (ν O–H), 3192 (ν N–H), 2947 (ν Csp3–H), 1140 (ν Csp2–H), 1158 (ν S=O), 690 (δ Csp2–H) cm⁻¹; 1H-NMR max 3440 (ν N–H), 3230 (ν Csp3–H), 1314 (ν Csp2–H).
(400 MHz, CDCl₃) δ 2.88 (bs, 1H, OH, D₂O exch.), 3.96 (d, 2H, J = 6.4 Hz, CH₂), 4.93 (bs, 2H, CH₂), 6.00 (t, 1H, J = 6.0 Hz, NH, D₂O exch.), 6.94–6.96 (bs, 1H, CH₉), 7.17–7.22 (m, 2H, CH₂), 7.33–7.39 (m, 2H, CH₂), 7.46–7.48 (m, 1H, CH₉), 7.83 (d, 1H, J = 7.6 Hz, CH₉); ¹³C-NMR (101 MHz, CDCl₃) δ 46.3 (CH₃), 64.0 (CH₂), 127.2 (Ar), 128.6 (Ar), 129.7 (Ar), 129.8 (Ar), 130.5 (Ar), 131.7 (Ar), 131.8 (Ar), 132.6 (Ar), 133.3 (Ar), 136.7 (Ar), 137.7 (Ar), 138.1 (Ar).

vtion was quenched with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column chromatography (EtOAc/n-hexane, 1:1). The title compound was a white solid (57% yield); mp 81–81.5°C; IR νmax 3547 (ν O–H), 3347 (ν N–O), 3316 (ν Csp2–H), 1318 (ν as S=O), 1138 (ν s S=O), 1153 (ν as S=O), 696 (δ Csp2–H) cm⁻¹; ¹H-NMR (400 MHz, CDCl₃) δ 2.98 (bs, 1H, OH, D₂O exch.), 4.51 (s, 2H, CH₂), 4.91 (s, 2H, CH₂), 5.59 (bs, 1H, NH, D₂O exch.), 7.25–7.79 (m, 7H, CH₉), 7.74–7.86 (m, 3H, CH₉), 8.05 (s, 1H, CH₉); ¹³C-NMR (101 MHz, CDCl₃) δ 45.6 (CH₃), 63.7 (CH₃), 123.2 (Ar), 125.2 (Ar), 126.0 (Ar), 126.6 (Ar), 127.0 (Ar), 128.4 (Ar), 128.7 (Ar), 129.0 (Ar), 130.0 (Ar), 131.1 (Ar), 131.4 (Ar), 131.5 (Ar), 133.2 (Ar), 133.7 (Ar), 137.6 (Ar), 138.3 (Ar).

2-(Hydroxymethyl)-N-(naphthalen-1-ylmethyl)benzenesulfonamide (19)

2-(Naphthalen-1-ylmethyl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide (1.0 eq.) was suspended in 20 mL of anhydrous methanol at room temperature. An excess of NaBH₄ was added portionwise and the reaction monitored by TLC. After 6 h the reaction was quenched with water and the aqueous phase was extracted with dichloromethane (3 x 30 mL). The organic layers were reunited, dried over sodium sulfate, and concentrated in vacuo to give a crude product which was purified by column chromatography (EtOAc/n-hexane, 1:1). The title compound was a yellow oil (88% yield); IR νmax 3477 (ν O–H), 3295 (ν N–H), 2935 (ν Csp3–H), 1317 (ν as S=O), 1160 (ν s S=O), 697 (δ Csp2–H) cm⁻¹; ¹H-NMR (400 MHz, CDCl₃) δ 2.89–2.95 (m, 1H, CH₂), 3.13–3.17 (m, 1H, CH₂), 3.64 (s, 3H, OCH₃), 4.41 (bs, 2H, CH₂), 4.58 (bs, 1H, OH), 4.87–4.91 (m, 1H, CH), 4.97 (bs, 1H, OH, D₂O exch.), 6.48 (bs, 1H, NH, D₂O exch.), 6.67–6.71 (m, 3H, CH₉), 7.07–7.11 (m, 1H, CH₉), 7.32–7.47 (m, 3H, CH₉), 7.87 (d, 1H, J = 7.6 Hz, CH₉); ¹³C-NMR (101 MHz, CDCl₃) δ 50.4 (CH₂), 55.1 (OCH₃), 60.6 (CH₂), 72.2 (CH), 111.4 (Ar), 113.3 (Ar), 118.1 (Ar), 128.2 (Ar), 129.5 (Ar), 129.6 (Ar), 131.2 (Ar), 133.2 (Ar), 137.3 (Ar), 138.6 (Ar), 142.5 (Ar), 159.5 (ArO).

Enzyme inhibition assays

An applied photophysics stopped-flow instrument has been used for assaying the CA-catalyzed CO₂ hydration activity. Phenol red (0.2 mM) has been used as indicator, working at the absorbance maximum of 557 nm, with 20 mM Hepes (pH 7.5, for χ-CAs) as buffer, and 20 mM NaClO₄ (for maintaining constant the ionic strength), following the initial rates of the CA-catalyzed CO₂ hydration reaction for a period of 10–100 s. The CO₂ concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor at least six traces of the initial 5–10% of the reaction have been used for determining the initial velocity. The uncatalyzed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of each inhibitor (1 µM) were prepared in distilled-deionized water and dilutions up to 0.1 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the E-I complex or for the eventual active site mediated hydrolysis of the inhibitor. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3 and the Cheng–Prusoff equation, and represent the average from at least three different determinations. All recombinant CA isoforms were obtained in-house as previously reported.

Molecular modeling studies

Preparation of saccharin-based structures

The saccharin-based analogs 1–21 were prepared in 3D with the MOE software package (v2013.08.02, Chemical Computing Group Inc., Montreal, Canada) as previously reported. All possible structural isomers of compounds were constructed. Strong acids were deprotonated and strong bases were protonated. Finally, the ligands were energy minimized using a steepest-descent protocol (MMFF94x force field).

Preparation of hCA crystal structures for docking studies

The structures of hCA I (PDB: 3LX, 1.90 Å), hCA II (PDB: 4E3D, 1.60 Å), hCA IX (PDB: 3AI1, 2.20 Å) and hCA XII (PDB: 1JD0, 1.50 Å) were obtained from the protein databank (PDB). The protein atoms, the active site zinc ions and the zinc-bound water molecule of hCA II were retained and all other atoms were omitted. The remaining structure was protonated using the MOE software package and subsequently the obtained structure was energy-minimized (AMBER99 force field). Finally, the obtained protein models were superposed on the hCA I structure using the backbone CA-atoms. The zinc-bound water molecule of hCA II coordinated well to the zinc ions of the other hCAs.
Docking studies
The GOLD Suite software package (v5.2, CCDC, Cambridge, UK) and the GoldScore scoring function were used to dock the derivatives into the hCA structures with and without the zinc-bound water molecule (25 dockings per ligand). The binding pocket was defined as all residues within 13 Å of a centroid (x: -17.071, y: 35.081, 43.681; corresponding approximately to the position of the thiadiazole ring of acetazolamide in the 1JD0 structure).

Results and discussion
The analysis of the biological data was accomplished comparing the open saccharin-based derivatives with their corresponding parent compounds in order to evaluate if the ring opening enhanced or reduced their biological activity.

All the tested compounds had no affinity for the common off-target hCA I and II isoforms (K<sub>i</sub> > 10000 nM) compared to their corresponding parent drugs. Moreover, our molecules with a benzyl alcohol group, instead of a carboxylic acid<sup>19</sup>, abolished completely this inhibitory activity improving the biological profile of this scaffold.

The inhibition profile of the open saccharin-based derivatives against the two tumor-related hCA IX and XII isoforms also displayed some important changes compared to parent drugs. Among the new open saccharin derivatives reported here, the best activity was obtained toward hCA XII isoform by compounds 1, 5, 6, 10 and 11, all provided of CH<sub>3</sub> or CF<sub>3</sub> groups. These molecules exhibited a slightly preference for hCA XII respect to hCA IX isoform, although the inhibition of the latter was also in the nanomolar range. Compound 5, containing a phenyl ring substituted with methyl group in meta position, had the highest inhibitory activity against hCA XII (K<sub>i</sub> = 4.3 nM), but also compound 6, containing a meta trifluoromethyl substituent on phenyl ring, exhibited similar inhibitory activity (K<sub>i</sub> = 4.4 nM). Comparable profile against hCA XII was observed for compounds 10 (K<sub>i</sub> = 5.7 nM) and 11 (K<sub>i</sub> = 7.2 nM), which are para substituted regioisomers of 5 and 6, respectively. Compound 1, which had a methyl group at ortho position of phenyl ring, showed similar inhibitory activity (K<sub>i</sub> hCA XII = 4.7 nM) with respect to 5 and 6. Other compounds with strong selectivity between hCA IX and XII were 9 (K<sub>i</sub> hCA IX = 267 nM, K<sub>i</sub> hCA XII = 64 nM) with bromine in meta position of phenyl ring, 12 (K<sub>i</sub> hCA IX = 126 nM, K<sub>i</sub> hCA XII = 57 nM) containing a cyano group in para position, 15 (K<sub>i</sub> hCA IX = 154 nM, K<sub>i</sub> hCA XII = 48 nM) which had a para chloro-substituted phenyl ring, 17 and 18 with, respectively, 2,6-difluoro and 3,4-dichloro-substituted phenyl rings.

Conversely, some compounds displayed a good selectivity towards hCA IX isoform. Compounds with nitro substituents in ortho (3), meta (7) or para (13) position of the ring had potent inhibitory activity preferentially against this overexpressed isomorph in the hypoxic tumoral niche.

For compounds 20 (K<sub>i</sub> hCA IX = 224 nM, K<sub>i</sub> hCA XII = 64 nM) and 21 (K<sub>i</sub> hCA IX = 31 nM, K<sub>i</sub> hCA XII = 355 nM), the reaction with NaBH<sub>4</sub> led to the further reduction of exocyclic carbonyl moiety. The presence of this additional group maintained the biological profile with a loss of inhibitory activity against hCA I and II and a preferential selectivity against the cancer-related isoforms.

Collectively, these promising data showed that the reductive ring opening of the saccharin nucleus improved the hCA inhibitory activity with a better selectivity with respect to the off-target isoforms. From the above, we also observed that the inhibition profile was affected positively or negatively by the substitution pattern.

Docking studies into the active site of hCA XII
The open saccharin analogs (compounds 1–21) were endowed with inhibition values in the nanomolar range against hCA XII isoform (K<sub>i</sub> values: 4.3–432 nM, Table 1, approximately 100-fold difference between lowest and highest K<sub>i</sub> values). The interaction of compound 6 with the active site of hCA XII was shown as an example (Figure 2). Docking studies indicated that the hydroxymethyl group and one of the sulfonamide oxygen atoms could interact simultaneously with the Zn<sup>2+</sup>-ion, whereas the other sulfonamide oxygen atom was water accessible. This oxygen might also form hydrogen bonds with the backbone of Thr199. The other polar substituents of the molecule were water accessible.

Conclusion
We proposed the design, synthesis, characterization and pharmacological evaluation in vitro of several new secondary sulfonamides based on the open saccharin scaffold as selective inhibitors of four different isoforms of human carbonic anhydrase. They were shown to be inactive against the two cytosolic off-target hCA I and II (K<sub>i</sub> > 10 μM); conversely, all these compounds inhibited hCA IX and XII in the low nanomolar range with K<sub>i</sub> ranging between 4.3 and 432 nM. The analysis of the K<sub>i</sub> values showed as the substituent on phenyl moiety that gives the best outcomes relative to inhibition of hCA XII isoform are methyl and trifluoromethyl groups.

Table 1. Inhibitory activity of the open saccharin-based derivatives 1–21 and acetazolamide as a reference drug, against selected hCA isoforms by a stopped-flow CO<sub>2</sub> hydrase assay.

<table>
<thead>
<tr>
<th>Compound</th>
<th>R</th>
<th>hCA I (nM)</th>
<th>hCA II (nM)</th>
<th>hCA IX (nM)</th>
<th>hCA XII (nM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2-CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>218</td>
<td>4.6</td>
</tr>
<tr>
<td>2</td>
<td>2-CF&lt;sub&gt;3&lt;/sub&gt;</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>200</td>
<td>54</td>
</tr>
<tr>
<td>3</td>
<td>2-NO&lt;sub&gt;2&lt;/sub&gt;</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>104</td>
<td>383</td>
</tr>
<tr>
<td>4</td>
<td>2-Br</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>113</td>
<td>323</td>
</tr>
<tr>
<td>5</td>
<td>3-CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>223</td>
<td>4.3</td>
</tr>
<tr>
<td>6</td>
<td>3-CF&lt;sub&gt;3&lt;/sub&gt;</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>238</td>
<td>4.4</td>
</tr>
<tr>
<td>7</td>
<td>3-NO&lt;sub&gt;2&lt;/sub&gt;</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>176</td>
<td>382</td>
</tr>
<tr>
<td>8</td>
<td>3-F</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>268</td>
<td>247</td>
</tr>
<tr>
<td>9</td>
<td>3-Br</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>267</td>
<td>64</td>
</tr>
<tr>
<td>10</td>
<td>4-CH&lt;sub&gt;3&lt;/sub&gt;</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>120</td>
<td>5.7</td>
</tr>
<tr>
<td>11</td>
<td>4-CF&lt;sub&gt;3&lt;/sub&gt;</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>253</td>
<td>7.2</td>
</tr>
<tr>
<td>12</td>
<td>4-CN</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>126</td>
<td>57</td>
</tr>
<tr>
<td>13</td>
<td>4-NO&lt;sub&gt;2&lt;/sub&gt;</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>20</td>
<td>54</td>
</tr>
<tr>
<td>14</td>
<td>4-F</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>26</td>
<td>63</td>
</tr>
<tr>
<td>15</td>
<td>4-Cl</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>154</td>
<td>48</td>
</tr>
<tr>
<td>16</td>
<td>4-Br</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>145</td>
<td>432</td>
</tr>
<tr>
<td>17</td>
<td>2,6-diF</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>296</td>
<td>45</td>
</tr>
<tr>
<td>18</td>
<td>3,4-diCl</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>298</td>
<td>40</td>
</tr>
<tr>
<td>19</td>
<td>2,3-Phenylene</td>
<td>&gt;10000</td>
<td>&gt;10000</td>
<td>294</td>
<td>345</td>
</tr>
</tbody>
</table>

*Mean from 3 different assays (errors were in the range of ±5–10% of the reported values).
The results were also rationalized by means of docking studies into the active site of hCA XII. Since these two cancer-related hCA isoforms were recently validated as drug targets, these results provided the development of new anticancer candidates.

**Declaration of interest**

The authors declare no conflict of interest.

This work was financed by two FP7 EU projects (Metoxia and Dynano) to CTS.

**References**


